TNXP — Topline Data for TNX-1300 Expected in Q3 2025
Jul 1, 2025, 5:00:00 AM UTC
Summary
Tonix Pharmaceuticals Holding Corp. has updated guidance for the timing of topline data from its Phase 2 study of TNX-1300, a drug candidate aimed at treating cocaine intoxication, which is now expected in Q3 2025. This information was released as part of a current report on January 8, 2025, outlining key developments and expectations surrounding the company's clinical trials. Investors should note that TNX-1300 is part of Tonix's broader strategy to develop innovative therapies addressing significant unmet medical needs, which may impact its market performance and investor interest in future results.
Company
TONIX PHARMACEUTICALS HOLDING CORP (TNXP)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.tonixpharma.comSimilar Events
Topline Data from 4FRONT-1 and 4FRONT-2 Expected in H2 2027
4D Molecular Therapeutics, Inc. anticipates topline data from its Phase 3 clinical trials, 4FRONT-1 and 4FRONT-2, in the second half of 2027. These trials evaluate the efficacy of the company's drug, 4D-150, for treating wet age-related macular degeneration (wet AMD). The trials aim to confirm that 4D-150 provides noninferior visual acuity compared to on-label applications of aflibercept and involve a target enrollment of 800 patients across both trials. This data will be crucial for potential regulatory submissions and may significantly impact the company’s market position in the ophthalmology space, which is poised for growth given the market need for effective treatments in this area.
Clinical Trial UpdateFDA PDUFA Goal Date for TNX-102 SL Approval
On December 23, 2024, Tonix Pharmaceuticals Holding Corp. announced that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on the marketing approval of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia. This product candidate aims to provide symptom relief for patients with fibromyalgia, which is characterized by chronic pain, fatigue, and other debilitating symptoms. The outcome of the FDA's decision could significantly impact Tonix Pharmaceuticals' market position and financial performance if approved.
Regulatory ApprovalFDA Decision on TNX-102 SL NDA Expected
The U.S. Food and Drug Administration (FDA) is expected to make a decision on the New Drug Application (NDA) for Tonix Pharmaceuticals' TNX-102 SL in August 2025, pending the acceptance of the NDA for standard review in December 2024. TNX-102 SL is a product candidate designed for the management of fibromyalgia. The company has recently expanded its leadership team to support the upcoming launch of TNX-102 SL and has updated the timeline for its clinical trial activities. The decision may have significant implications for Tonix Pharmaceuticals' market position in the treatment of fibromyalgia and related conditions.
FDA DecisionTarget Date for NDA Filing for CTx-1301
Cingulate Inc. aims to file a New Drug Application (NDA) for CTx-1301 in mid-2025. CTx-1301 is a drug candidate intended for potential FDA approval. The company secured a $5.48 million promissory note from Streeterville Capital, LLC to support its operations. The note includes a $450,000 original issue discount, a 9% interest rate, and matures in 18 months. Proceeds will be used for working capital and corporate purposes, ensuring sufficient funding for clinical, manufacturing, and regulatory activities until late 2025. Upon default, including failure to pay or bankruptcy, penalties increase the outstanding balance. Meanwhile, the company cannot enter variable rate transactions until July 2025. CTx-1301's NDA filing is strategically important as it aligns with this funding, suggesting potential progress in its approval journey.
FDA NDA filing